Niraparib and Dostarlimab in HRD Solid Tumors
Phase 2
Recruiting
- Conditions
- Homologous Recombination Deficient Solid Tumors
- Interventions
- Drug: Combination drug
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- West Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT04983745
- Locations
- 🇺🇸
West Cancer Center, Germantown, Tennessee, United States
Evaluation of a Mobile App to Promote Social Support for Oncology Patients
Not Applicable
Completed
- Conditions
- Chemotherapy Effect
- Interventions
- Behavioral: Comparator App
- First Posted Date
- 2020-04-02
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- West Cancer Center
- Target Recruit Count
- 230
- Registration Number
- NCT04331678
- Locations
- 🇺🇸
West Cancer Center, Memphis, Tennessee, United States
Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast
Phase 2
Active, not recruiting
- Conditions
- Early-stage Breast CancerTriple Negative Breast CancerHER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- West Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT03812393
- Locations
- 🇺🇸
West Cancer Center, Germantown, Tennessee, United States
Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
Phase 1
- Conditions
- BRAF Gene MutationMelanoma
- Interventions
- Drug: Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,VilDrug: Talimogene Laherparep 100 Mil Pfu/Ml 1Ml
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- West Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT03088176
- Locations
- 🇺🇸
West Cancer Center, Germantown, Tennessee, United States
© Copyright 2025. All Rights Reserved by MedPath